DCT

1:26-cv-00243

Kaneka Corp v. Danimer Scientific LLC

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00243, D. Del., 05/20/2026
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware because both defendants are Delaware corporations and therefore reside in the judicial district.
  • Core Dispute: Plaintiff alleges that Defendants’ biodegradable resin compounds and products made therefrom infringe two patents related to specific formulations of polyhydroxyalkanoate (PHA) polymers.
  • Technical Context: The technology relates to biobased, biodegradable polymers intended as alternatives to traditional oil-based plastics for applications such as food packaging, cutlery, and drinking straws.
  • Key Procedural History: The complaint alleges that prior to this suit, Defendant Teknor Apex Company acquired the assets of a bankrupt third-party, Danimer Scientific, Inc. (DSI). Plaintiff had previously put DSI on notice of infringement allegations via filings in DSI's Chapter 11 bankruptcy case. Plaintiff further alleges it provided Defendant Teknor with actual notice of the alleged infringement before and after the asset acquisition, forming a basis for its willfulness claims.

Case Timeline

Date Event
2012-08-03 ’934 Patent Priority Date
2013-10-11 ’117 Patent Priority Date
2016-10-25 ’934 Patent Issue Date
2018-07-24 ’117 Patent Issue Date
2024-10-01 Kaneka obtains and tests biodegradable straws made from predecessor's (DSI) compound (approx.)
2024-12-31 Kaneka identifies DSI as its leading competitor in the U.S. (approx.)
2025-03-18 DSI files for Chapter 11 bankruptcy protection
2025-04-22 Kaneka files objection in DSI bankruptcy, asserting patent infringement claims
2025-04-24 Kaneka files Motion for Stay Relief in DSI bankruptcy, including a draft infringement complaint
2025-05-01 Teknor enters agreement to acquire DSI assets (approx.)
2025-05-23 Kaneka sends email to Teknor's CEO regarding patent infringement claims
2025-06-01 Kaneka and Teknor's CEO begin communications to resolve dispute (approx.)
2025-07-01 Kaneka sends letters to potential customers of Defendants regarding infringement (approx.)
2025-08-02 Teknor's CEO emails Kaneka acknowledging communications to "our customers"
2025-10-07 Kaneka learns its customer WinCup, Inc. purchased an accused Danimer Compound
2025-10-23 Eagle Beverage informs Kaneka it could source PHA polymers from Defendants
2025-11-27 Teknor's CEO sends letter to Kaneka regarding the asserted patents
2026-05-20 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,475,934 - "Polyester Resin Composition and Molded Article Containing This Resin Composition", issued October 25, 2016

  • The Invention Explained:
    • Problem Addressed: The patent addresses the slow crystallization speed of polyhydroxyalkanoate (PHA), a type of biodegradable plastic. This slowness hinders manufacturing productivity in processes like injection molding and can cause the final product's mechanical properties to change undesirably over time ('934 Patent, col. 1:36-44).
    • The Patented Solution: The invention introduces pentaerythritol into the PHA composition to act as a "crystal nucleating agent." This additive significantly speeds up the rate of crystallization and solidification after the resin is melted, improving processing speed and the stability of the final molded article ('934 Patent, abstract; '934 Patent, col. 2:54-61).
    • Technical Importance: By improving the crystallization rate, the invention makes PHAs more suitable for high-speed, high-volume molding processes, enhancing their commercial viability as an alternative to conventional plastics ('934 Patent, col. 2:40-50).
  • Key Claims at a Glance:
    • The complaint asserts independent claim 1 (Compl. ¶88).
    • The essential elements of independent claim 1 are:
      • An aliphatic polyester resin composition, comprising:
      • a polyhydroxyalkanoate copolymer; and
      • a crystal nucleating agent comprising pentaerythritol,
      • wherein the polyhydroxyalkanoate copolymer includes a repeating unit of 3-hydroxybutyrate at a composition ratio of from 80 mol % to 99 mol %.
    • The complaint reserves the right to assert dependent claims 2-6, 8-9, 11, 12 and 20 (Compl. ¶89).

U.S. Patent No. 10,030,117 - "Aliphatic Polyester Resin Composition and Aliphatic Polyester Resin Molded Article", issued July 24, 2018

  • The Invention Explained:
    • Problem Addressed: The patent addresses a problem known as "bloom" or "bleedout," where organic additives like the crystal nucleating agent pentaerythritol can ooze out from the surface of a molded PHA product over time ('117 Patent, col. 2:20-25). This phenomenon can negatively affect the product's appearance and surface quality.
    • The Patented Solution: The invention adds a third component, a "filler," to the composition of PHA and pentaerythritol. The specification explains that this filler—which can be an inorganic material like calcium carbonate or an organic material like wood powder—suppresses the bloom of the nucleating agent, improves surface smoothness, and enhances the product's ability to be released from a mold ('117 Patent, abstract; '117 Patent, col. 2:29-34).
    • Technical Importance: This solution enhances the manufacturability and long-term quality of PHA products, particularly for consumer goods where surface finish and stability are critical, by preventing the undesirable surface bleedout of additives ('117 Patent, col. 2:40-47).
  • Key Claims at a Glance:
    • The complaint asserts independent claims 1 and 13 (Compl. ¶95).
    • The essential elements of independent claim 1 include:
      • An aliphatic polyester resin composition comprising:
      • a polyhydroxyalkanoate (A);
      • pentaerythritol (B); and
      • a filler (C),
      • wherein the PHA is one of several specified copolymers, the filler is of a specified type (e.g., silicate, carbonate) and amount (10 to 100 parts by weight), and the pentaerythritol is present in a specified amount (0.3 to 5 parts by weight).
    • The essential elements of independent claim 13 are similar, framing the composition as comprising a PHA (A), a crystal nucleating agent comprising pentaerythritol (B), and a filler (C).
    • The complaint reserves the right to assert several dependent claims (Compl. ¶96).

III. The Accused Instrumentality

  • Product Identification: The accused instrumentalities are certain resin compounds referred to as "Danimer Compounds" and products molded from them, known as "Danimer Products" (Compl. ¶2). The compounds are marketed under names including "Nodax® PHA polymers" (Compl. ¶39).
  • Functionality and Market Context: The Danimer Compounds are resin pellets comprising polyhydroxyalkanoate (PHA), specifically poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) or PHBH (Compl. ¶¶59, 61). The complaint alleges these pellets are sold to manufacturers who use them to create biodegradable end-products, such as drinking straws (Compl. ¶70). The complaint presents a table detailing the chemical analysis of an accused "Danimer Compound" sample, alleging it contains PHBH, pentaerythritol (PETL), poly(butylene succinate-co-adipate) (PBSA), and calcium carbonate (CaCO3) (Compl. ¶61). The complaint alleges these compounds and the resulting products compete directly with Plaintiff's "Green Planet®" line of polymers for the same customers and applications (Compl. ¶¶81-82). An advertisement included in the complaint shows "New Biodegradable PHA Straws from Eagle!" developed "in collaboration with Danimer Scientific's Nodax™" (Compl. ¶70, p. 15).

IV. Analysis of Infringement Allegations

'934 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
a polyhydroxyalkanoate copolymer... wherein the polyhydroxyalkanoate copolymer includes a repeating unit of 3-hydroxybutyrate at a composition ratio of from 80 mol % to 99 mol % The accused Danimer Compound pellets contain PHBH, a PHA copolymer. The complaint's analysis alleges the 3-hydroxybutyrate (HB) molar percentage is 97.7%, which falls within the claimed range. ¶¶59, 61 col. 3:55-62
a crystal nucleating agent comprising pentaerythritol The accused Danimer Compound pellets are alleged to contain 0.51 parts by weight of PETL, which the complaint defines as pentaerythritol. ¶¶59, 61 col. 5:25-30

'117 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
a polyhydroxyalkanoate (A) The accused Danimer Compound pellets are alleged to contain PHBH, a type of polyhydroxyalkanoate. ¶61 col. 4:38-54
pentaerythritol (B) The accused Danimer Compound pellets are alleged to contain PETL, which the complaint identifies as pentaerythritol. ¶¶59, 61 col. 5:29-41
a filler (C) The accused Danimer Compound pellets are alleged to contain 21 parts by weight of CaCO3 (calcium carbonate), an inorganic filler explicitly listed in the patent. ¶61 col. 5:11-15
  • Identified Points of Contention:
    • Factual Questions: The infringement analysis will likely depend on factual verification of the complaint's chemical analysis. A central question will be whether the tested samples are representative of all accused Danimer Compounds and whether Defendants' own data confirms the presence and proportions of PHBH, pentaerythritol, and a filler as alleged. Another advertisement shows "phade" straws are "Developed with Polyhydroxyalkanoate (PHA) by Danimer Scientific, Inc.", reinforcing the link between the defendant and the technology (Compl. ¶71, p. 16).
    • Scope Questions: A potential issue may arise regarding the function of every component in the accused mixture. For example, the complaint alleges the presence of PBSA in the Danimer Compound (Compl. ¶61). This raises the question of whether PBSA functions as an additional PHA, a plasticizer, a filler, or something else, and how that classification affects the infringement analysis under the patent claims.

V. Key Claim Terms for Construction

  • The Term: "crystal nucleating agent" ('934 Patent, Claim 1; '117 Patent, Claim 13)

    • Context and Importance: This term is the technological core of the '934 patent and a key component of the '117 patent. The patents are premised on using pentaerythritol for this specific function. Practitioners may focus on this term because Defendants could argue that pentaerythritol in their formulation serves a different primary purpose or that its nucleating effect is incidental, in an attempt to avoid infringement.
    • Intrinsic Evidence for a Broader Interpretation: The '934 patent provides a functional definition, stating a nucleating agent "refers to one that acts as a nucleus for crystallization" ('934 Patent, col. 2:65-67). This language may support a construction based on the effect of the substance rather than its label.
    • Intrinsic Evidence for a Narrower Interpretation: The '934 patent specification consistently and specifically identifies pentaerythritol as the solution to the technical problem ('934 Patent, col. 2:54-61). A party could argue that the term, in the context of the patent, should be understood as the primary substance added specifically for nucleation, potentially limiting its scope if other agents are present.

  • The Term: "filler" ('117 Patent, Claim 1)

    • Context and Importance: The addition of a "filler" is the key inventive concept of the '117 patent, introduced to solve the "bloom" problem. The complaint alleges the accused product contains calcium carbonate (CaCO3), an explicit example of a filler in the patent. The definition of this term is critical to determining the scope of the '117 patent and whether all components of the accused product might be considered.
    • Intrinsic Evidence for a Broader Interpretation: The specification describes a filler as being "typically used to improve the mechanical properties or an additive used to improve productivity" and provides a long list of both inorganic and organic examples ('117 Patent, col. 5:11-22). This suggests a broad, functional definition.
    • Intrinsic Evidence for a Narrower Interpretation: The patent separately discusses "plasticizers" ('117 Patent, col. 7:29-32). Defendants may argue that a substance with other active properties (e.g., a plasticizing effect) does not qualify as a "filler," which they might contend should be construed as a more inert or passive bulking agent.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement. Inducement is premised on Defendants allegedly selling the Danimer Compounds to customers like WinCup and Eagle Beverage with the specific intent to encourage them to manufacture infringing end-products, such as straws (Compl. ¶¶109-110). Contributory infringement is based on allegations that the Danimer Compounds are a material part of the invention, are not staple articles of commerce, and have no substantial non-infringing uses (Compl. ¶102).
  • Willful Infringement: The complaint makes detailed allegations to support willfulness. It alleges Defendants had pre-suit knowledge of the patents and infringement contentions through Kaneka's filings in the DSI bankruptcy (Compl. ¶25), through due diligence during the acquisition of DSI's assets (Compl. ¶27), and via direct written notice to Teknor's CEO beginning in May 2025 (Compl. ¶33). Continued alleged infringement after this extensive notice is the basis for the willfulness claim (Compl. ¶80).

VII. Analyst’s Conclusion: Key Questions for the Case

  • A central factual question will be one of compositional identity: Will discovery validate the complaint’s lab analysis, confirming that the commercially distributed Danimer Compounds consistently contain a PHA copolymer, pentaerythritol, and a filler within the claimed parameters of the '934 and '117 patents?
  • A primary legal question will concern scienter and willfulness: Given the detailed history of notice alleged in the complaint, including bankruptcy filings and direct executive communications, can Defendants mount a credible defense against the claims of willful and induced infringement by arguing a good-faith belief of non-infringement or invalidity?
  • The case may also turn on a question of claim construction: How will the court define "filler" in the '117 patent? A broad functional definition could encompass multiple components in the accused product, whereas a narrower definition limited to inert bulking agents could create a path for a non-infringement argument based on the multi-functional nature of some polymer additives.
Loading Amended Complaint